Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.

Non-ischaemic cardiomyopathies (NICMs) are chronic, progressive myocardial diseases with distinct patterns of morphological, functional, and electrophysiological changes. In the setting of cardiomyopathy (CM), determining the exact aetiology is important because the aetiology is directly related to treatment and patient survival. Determining the exact aetiology, however, can be difficult using currently available imaging techniques, such as echocardiography, radionuclide imaging or X-ray coronary angiography, since overlap of features between CMs may be encountered. Cardiovascular magnetic resonance (CMR) imaging has recently emerged as a new non-invasive imaging modality capable of providing high-resolution images of the heart in any desired plane. Delayed contrast enhanced CMR (DE-CMR) can be used for non-invasive tissue characterization and may hold promise in differentiating ischaemic from NICMs, as the typical pattern of hyperenhancement can be classified as 'ischaemic-type' or 'non-ischaemic type' on the basis of pathophysiology of ischaemia. This article reviews the potential of DE-CMR to distinguish between ischaemic and NICM as well as to differentiate non-ischaemic aetiologies. Rather than simply describing various hyperenhancement patterns that may occur in different disease states, our goal will be (i) to provide an overall imaging approach for the diagnosis of CM and (ii) to demonstrate how this approach is based on the underlying relationships between contrast enhancement and myocardial pathophysiology.

[1]  K. Raghuram,et al.  Clinical Magnetic Resonance Imaging, 3rd ed., vol. 2. , 2007 .

[2]  H. Hishida,et al.  Feasibility of diagnosing chronic myocarditis by endomyocardial biopsy , 2007, Heart and Vessels.

[3]  M. Penicka,et al.  741 Assessment of myocardial viability by contrast echocardiography in patients with chronic ischemic left ventricle dysfunction. Comparison with late gadolinium-enhanced cardiovascular magnetic resonance , 2005 .

[4]  P. Poole‐Wilson,et al.  Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2005, Circulation.

[5]  Dudley J Pennell,et al.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[6]  Udo Sechtem,et al.  Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology , 2004, Circulation.

[7]  D. Pennell,et al.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. , 2003, European heart journal.

[8]  Dipan J. Shah,et al.  Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing &bgr;-Blocker Therapy , 2003, Circulation.

[9]  C H Lorenz,et al.  Differentiation of Heart Failure Related to Dilated Cardiomyopathy and Coronary Artery Disease Using Gadolinium‐Enhanced Cardiovascular Magnetic Resonance , 2003, Circulation.

[10]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[11]  H. Mahrholdt 755 Relation of myocardial scarring to clinical risk factors for sudden death in hypertrophic cardiomyopathy , 2003 .

[12]  J. Schulz-Menger,et al.  Long-term follow-up of patients with acute myocarditis by magnetic resonance imaging , 2003, Magnetic Resonance Materials in Physics, Biology and Medicine.

[13]  R. Kim,et al.  Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study , 2003, The Lancet.

[14]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[15]  Charles B. Higgins,et al.  Cardiovascular MRI and MRA , 2002 .

[16]  O. Vignaux,et al.  Detection of Myocardial Involvement in Patients with Sarcoidosis Applying T2-Weighted, Contrast-Enhanced, and Cine Magnetic Resonance Imaging: Initial Results of a Prospective Study , 2002, Journal of computer assisted tomography.

[17]  R. Judd,et al.  Assessment of Myocardial Viability by Cardiovascular Magnetic Resonance Imaging , 2022 .

[18]  P. Elliott,et al.  Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy , 2002, Circulation.

[19]  C. O'connor,et al.  A standardized definition of ischemic cardiomyopathy for use in clinical research. , 2002, Journal of the American College of Cardiology.

[20]  Wolfgang G Rehwald,et al.  Myocardial Magnetic Resonance Imaging Contrast Agent Concentrations After Reversible and Irreversible Ischemic Injury , 2002, Circulation.

[21]  Ali Massumi,et al.  Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. , 2002, Texas Heart Institute journal.

[22]  R. Kim,et al.  Visualization of Discrete Microinfarction After Percutaneous Coronary Intervention Associated With Mild Creatine Kinase-MB Elevation , 2001, Circulation.

[23]  Edwin Wu,et al.  Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction , 2001, The Lancet.

[24]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[25]  W J McKenna,et al.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease , 2000, Heart.

[26]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[27]  E. Topol,et al.  Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.

[28]  ICHAEL,et al.  UNDERLYING CAUSES AND LONG-TERM SURVIVAL IN PATIENTS WITH INITIALLY UNEXPLAINED CARDIOMYOPATHY , 2000 .

[29]  T. Parrish,et al.  Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. , 1999, Circulation.

[30]  R. Virmani,et al.  Plaque rupture and sudden death related to exertion in men with coronary artery disease. , 1999, JAMA.

[31]  C. Kawai,et al.  From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. , 1999, Circulation.

[32]  L. Arroyo,et al.  Mechanisms of plaque rupture: mechanical and biologic interactions. , 1999, Cardiovascular research.

[33]  O Strohm,et al.  Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. , 1998, Circulation.

[34]  W. Mckenna,et al.  Management of hypertrophic cardiomyopathy. , 1993 .

[35]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[36]  B. McManus,et al.  Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets , 1996, Journal of virology.

[37]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[38]  S. Coughlin,et al.  Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.

[39]  W. Roberts,et al.  Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. , 1993, The American journal of cardiology.

[40]  W. Roberts,et al.  Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[41]  W. Mckenna,et al.  The management of hypertrophic cardiomyopathy. , 1997, The New England journal of medicine.

[42]  M. Fujimura,et al.  MR and CT in the evaluation of sarcoid myopathy. , 1991, Journal of computer assisted tomography.

[43]  J. Bender Idiopathic dilated cardiomyopathy. An immunologic, genetic, or infectious disease, or all of the above? , 1991, Circulation.

[44]  R. Edelman,et al.  Clinical magnetic resonance imaging , 1990 .

[45]  A. J. Hauck,et al.  Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. , 1989, Mayo Clinic proceedings.

[46]  B. McManus,et al.  Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. , 1987, The American journal of cardiology.

[47]  W. Edwards,et al.  Myocarditis. A histopathologic definition and classification. , 1987, The American journal of cardiovascular pathology.

[48]  G L Wolf,et al.  Relaxation of water protons in the intra‐ and extracellular regions of blood containing Gd(DTPA) , 1986, Magnetic resonance in medicine.

[49]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[50]  P. Yu,et al.  Progress in Cardiology , 1985 .

[51]  Z. Krajcer,et al.  Coronary artery disease in hypertrophic cardiomyopathy. , 1985, The American journal of cardiology.

[52]  B. Bulkley,et al.  Ischemic cardiomyopathy: a clinicopathologic study of fourteen patients. , 1980, American heart journal.

[53]  W. Roberts,et al.  Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. , 1979, The American journal of cardiology.

[54]  K. R. Anderson,et al.  Histopathological types of cardiac fibrosis in myocardial disease , 1979, The Journal of pathology.